Summary
The mCRPC market, valued at around USD 8 billion in 2025, is undergoing rapid disruption driven by scientific innovation, patent expirations, and shifting treatment paradigms.
Once dominated by blockbuster androgen receptor inhibitors like ZYTIGA and XTANDI, the landscape is now fragmenting under pressure from generic competition, precision medicine, and emerging therapies such as radioligand treatments.
Legacy leaders such as Johnson & Johnson, Pfizer, Astellas, GSK, Sanofi, AstraZeneca, and Merck are already losing ground.
The metastatic castration-resistant prostate cancer (mCRPC) market is in the middle of a seismic transformation. Radiol...
